Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

168
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
168
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220
Human Genetics01:28

Human Genetics

557
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
557
Bipolar Disorder01:30

Bipolar Disorder

65
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
65
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

54
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
54

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immersive Technologies for Cognitive Rehabilitation in Dementia and Mild Cognitive Impairment: Systematic Review.

Journal of medical Internet research·2026
Same author

Neuropsychiatric and behavioural correlates of sundowning in Alzheimer's disease.

International journal of psychiatry in clinical practice·2026
Same author

Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study.

Molecular psychiatry·2026
Same author

Polygenic score for schizophrenia worsens the effect of bipolar disorder course on neuronal metabolism and white matter microstructure.

Psychiatry and clinical neurosciences·2026
Same author

Multilingualism and international mental health research-The barriers for non-native speakers of English.

PLOS mental health·2026
Same author

Genomic analyses reveal new insights into Alzheimer's disease.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Jun 24, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.2K

Precision medicine in mood disorders.

Alessandro Serretti1

  • 1Department of Biomedical and NeuroMotor Sciences University of Bologna Bologna Italy.

PCN Reports : Psychiatry and Clinical Neurosciences
|June 13, 2024
PubMed
Summary
This summary is machine-generated.

Precision medicine aims to tailor treatments for mood disorders. Pharmacogenetic applications, using genetic variants, show promise for optimizing medication selection and improving patient outcomes.

Keywords:
antidepressantsdepressionprecision medicinepsychiatrypsychopharmacology

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K

Related Experiment Videos

Last Updated: Jun 24, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.2K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Genetics

Background:

  • Selecting psychoactive medications for mood disorders is challenging due to numerous drug options and common response/tolerability issues.
  • Trial and error is often necessary, highlighting the need for precision medicine to optimize treatment outcomes.
  • Biological factors, including genetic variations, are increasingly recognized for their potential to refine treatment predictions.

Purpose of the Study:

  • To explore the role of pharmacogenetics in precision medicine for mood disorder treatment.
  • To discuss the current state and future prospects of genetic applications in psychiatric pharmacotherapy.
  • To emphasize the integration of clinical, pharmacokinetic, and genetic factors for personalized treatment strategies.

Main Methods:

  • Review of existing literature on gene variants and their impact on antidepressant response.
  • Analysis of the current debate surrounding the clinical utility of pharmacogenetic testing.
  • Discussion of the potential of cumulative genetic scores for predicting psychiatric disorder liability and treatment outcomes.

Main Results:

  • While the benefit of central nervous system gene variants is debated, metabolic gene variants are generally accepted for guiding treatment.
  • Pharmacogenetic tools are evolving, with genome-wide composite genetic scores poised to enhance predictive capabilities.
  • Clinical and pharmacokinetic factors are currently used for precision medicine in mood disorders, with genetic data expected to augment these approaches.

Conclusions:

  • Precision medicine offers a path to optimize treatment for mood disorders by integrating diverse patient data.
  • Pharmacogenetics, particularly metabolic gene variants and future genome-wide scores, holds significant promise for personalized psychiatric care.
  • Combining clinical insights with comprehensive genetic information represents the most promising future direction for targeted mood disorder therapies.